DAPT duration in acute coronary syndrome: is stent type an issue?

EuroIntervention 2021;17:360-361. DOI: 10.4244/EIJV17I5A62

Martine Gilard
Martine Gilard1, MD, PhD; Romain Didier1, PhD, MD
1. CHRU Brest, Brest, France
After numerous large randomised trials, it is now broadly admitted by the entire cardiology community that at least 12 months’ dual antiplatelet therapy (DAPT) with a P2Y12 receptor inhibitor in combination with aspirin is recommended in patients with acute coronary syndromes (ACS) managed by coronary stent implantation, except in case of a high risk of bleeding1. The ultimate goal of longer rather than shorter DAPT is to prevent thrombus formation in future plaque rupture in patients with a history of ACS, who are at greater risk of ischaemic events than those without, mostly due to plaque destabilisation2. In ACS ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Subcutaneous RUC-4 for acute myocardial infarction: a new treatment on the horizon for pre-hospital care?

Latest news